Join
Live feed
·
NEWSReleasevia Quantisnow
Aeterna Zentaris Inc. logo

Aeterna Zentaris Completes Phase 3 DETECT-Trial For Macimorelin In Diagnosing Childhood Onset Growth Hormone Deficiency; Top-Line Data And Full Study Results Expected In Q3 2024

ByQuantisnow·Wall Street's wire, on your screen.
AEZS· Aeterna Zentaris Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AEZS (Aeterna Zentaris Inc.) and more on Quantisnow.